Sana Biotechnology To Present Data From Allogeneic Primary Islet Cell Therapy At European Association For The Study Of Diabetes
Sana Biotechnology, Inc. (NASDAQ: SANA ), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered wi